SPA Pricing Education, Analytics & Decision Making Tools Webinar Series

Health care execs are sweating over pricing pressure | Axios

axios

Public outcry over high prices for drugs and health care services has caught the attention of the people who decide those prices. But that doesn’t mean there will be any immediate action. A new survey from investment bank Lazard found that more than half (57%) of 300 U.S. and European health care executives and investors said pricing and reimbursement was the top challenge for them right now.

The problem is even more acute for the drug industry, especially in light of President Trump’s occasionally harsh words. About 88% of U.S. pharma executives view pricing as the top pressure. David Gluckman, the co-head of health care at Lazard, told me that survey respondents believe pricing actions will be “driven by the government, but also significantly influenced by health insurers.”

Read complete article here:

Health care execs are sweating over pricing pressure – Axios.